Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the erb family of oncogenes and to damage genomic DNA

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 484-491

  Brahimi, Fouad ^a   Rachid, Zakaria ^a   Qiu, Qiyu ^a   McNamee, James P ^b   Li, Yu Jiang ^c   Tari, Ana M ^c   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Combi molecules; Cytotoxic DNA alkylating agent; EGFR HER2 overexpressing breast cell lines; Quinazolines

Indexed keywords

6 ACRYLAMIDOQUINAZOLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; GENOMIC DNA; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ZR 01; ZR 2002;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; AUTOPHOSPHORYLATION; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; ONCOGENE C ERB; PRIORITY JOURNAL; RESPONSE TIME; SEQUENCE HOMOLOGY; SERUM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DNA DAMAGE; DNA, NEOPLASM; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MOLECULAR STRUCTURE; ONCOGENE PROTEINS V-ERBB; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 6344231968     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20383     Document Type: Article

References (27)

1. Neal DE, March C, Bennett MK, Abel PD, Hall RR, Sainbury JR, Harris AL. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1: 366-8.
2. Gross ME, Zorbas MA, Danels YJ, Garcia R, Gallick GE, Olive M, Brattain MG, Boman BM, Yeoman LC. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991;51:1452-9.
3. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 1992;52:3089-93.
4. Koenders PG, Beex LV, Guerts-Moespat A, Heuvel JJ, Kienhuis CB, Benraad TJ. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 1991;51:4544-8.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
6. Carraway KL 3rd, Cantley LC. A Neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
7. Stebbing J, Copson E, O'Reilly S. Herceptin (trastuzumab) in advanced breast cancer. Cancer Treat Rev 2000;26:287-90.
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
9. Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, Fry DW. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995;38:3482-7.
10. Rewcastle GW, Bridges AJ, Fry DW, Rubin JR, Denny WA. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J Med Chem 1997;40:1820-6.
11. Rewcastle GW, Murray DK, Elliot WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters TR, Denny WA. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem 1998;41:742-51.
12. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82:207-18.
13. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, et al. Specific irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7.
14. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka L, Showalter HD, Vincent PW, Elliott WL, Denny A. Tyrosine kinase inhibitors 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6- acrylaminde bearing additional solubilizing functions. J Med Chem 2000;43:1380-97.
15. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
16. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenograft in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002;8:3870-6.
17. Brahimi F, Matheson SL, McNamee JP, Tari A, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "combi- triazene" BJ2000, a new probe for the Combi-Targeting postulates. J Pharm Exp Ther 2002;303:238-46.
18. Matheson SL, McNamee JP, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharm Exp Ther 2001;296:832-40.
19. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ. The combi-targeting concept: a novel 3,3-disubstitued nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003;51:1-10.
20. Rachid Z, Brahimi F, Teoh N, Katsoulas A, Jean-Claude BJ. Chemical dissection of the binary properties of a series of combi-triazenes. J Med Chem 2003;46:4313-21.
21. Tari AM, Lopez-Berestein G. Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-overexpressing cells, respectively. Int J Cancer 2000;86:295-7.
22. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990;82:1107-12.
23. Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem 1996;271:28753-6.
24. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-6.
25. Davis RJ. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995;42:459-67.
26. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002;277:33490-500.
27. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulates the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiation Res 2003;159:439-52.